Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck, Modifi
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of the deal, the U.S.
Merck buys Modifi for $30M plus up to $1.3B in potential payments
Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and up to $1.3B in potential milestone payments. Modifi, a spinout of Yale University,
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma.
Merck acquires Modifi Biosciences for $30M upfront
Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary,
Merck & Co buys Modifi Biosciences
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co (NYSE: MRK). Modifi Biosciences was formed in 2021 based on technology spun out of Yale University.
Merck acquires Yale-spinout Modifi Bio in $1.3B deal
Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by biopharmaceutical giant Merck & Co. Inc. in a $1.3 billion deal, the companies announced Wednesday.
Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences
Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.
BioWorld
22h
Modifi acquired by Merck in $1.3B deal
Modifi
Biosciences
Inc. has come a long way very quickly. Spun out of Yale University in 2021, it published data on DNA ...
BioPharma Dive
6h
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...
pharmaphorum
11d
Merck bulks up in haematology, buying Imago for $1.35bn
Merck
& Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago
BioSciences
and its bomedemstat drug candidate for blood disorders.
6h
Merck & Company (MRK) Receives a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback